370 related articles for article (PubMed ID: 31362369)
21. Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.
Greve P; Beishuizen A; Hagleitner M; Loeffen J; Veening M; Boes M; Peperzak V; Diez C; Meyer-Wentrup F
Front Immunol; 2023; 14():1229558. PubMed ID: 37583696
[TBL] [Abstract][Full Text] [Related]
22. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
[TBL] [Abstract][Full Text] [Related]
23. Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin's Lymphoma.
Yu TY; Dai MS
J Hematol; 2020 Apr; 9(1-2):30-32. PubMed ID: 32362983
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
[TBL] [Abstract][Full Text] [Related]
25. How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.
Mei M; Chen R
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):26-33. PubMed ID: 29233742
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
27. Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.
Ma H; Li X; Lin M; Lv K; Zhang M; Wu X
Am J Transl Res; 2021; 13(11):12206-12216. PubMed ID: 34956447
[TBL] [Abstract][Full Text] [Related]
28. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
Moskowitz AJ; Herrera AF; Beaven AW
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
[TBL] [Abstract][Full Text] [Related]
30. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C; Allen P; Herrera AF
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
[TBL] [Abstract][Full Text] [Related]
31. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
Illés Á; Jóna Á; Miltényi Z
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
35. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
39. A review of pathobiology and therapies for classic Hodgkin lymphoma.
Khan M; Hagemeister F; Wang M; Ahmed S
Blood Rev; 2022 Sep; 55():100949. PubMed ID: 35396126
[TBL] [Abstract][Full Text] [Related]
40. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
